---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-035597"
form_type: "8-K/A"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2025-11-18T23:59:59+00:00"
generated_at: "2026-05-16T18:50:12.781368+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Eton files historical financials for Increlex acquisition; product net sales $18.7M in 2023

## Summary
- Acquired Increlex for $22.5M upfront plus $7.5M inventory; $2.5M payments on 1st & 2nd anniversaries.
- Expanded credit facility to $30M, maturity 3 years, SOFR+6.75%; issued warrant for 289,736 shares at $5.32.
- Increlex net sales: $18.7M (2023), $15.1M (2022); nine months Sep 2024 $13.0M vs $13.9M prior.
- Pro forma combined net loss for nine months Sep 2024: $5.5M vs Eton historical $3.2M.
- Increlex net sales exceeded direct expenses: $3.9M in 2023, $4.1M in nine months Sep 2024.

## SEC filing metadata
- accession: 0001437749-25-035597
- form_type: 8-K/A
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2025-11-18T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.01, 9.01, 8.01, 9.0
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774925035597/0001437749-25-035597-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774925035597/eton20250314_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-035597
- JSON: https://secwatch.observer/filing/0001437749-25-035597.json
- Plain text: https://secwatch.observer/filing/0001437749-25-035597.txt

## Source-grounded claims
- claim_id: ae5ea290b03751abab29fc49ecba3004f1b1be84
  claim: Eton Pharmaceuticals, Inc. completed an acquisition involving Ipsen S.A. (closed 2024-12-19).
  evidence_excerpt: on December 1 9, 2024, the Company completed its purchase (the “Acquisition”) of Increlex® (“Increlex”) from Ipsen S.A. (“Ipsen”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710340/000143774925035597/0001437749-25-035597-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.